We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025.
The ADPD 2025 Conference is a premier global event that gathers top researchers and industry leaders to share groundbreaking advancements in Alzheimer’s, Parkinson’s, and related neurodegenerative disorders such as Amyotrophic lateral sclerosis (ALS). This year’s theme, “Striving for a Better Future for All Those Affected by Neurodegenerative Diseases” highlights the importance of collaboration in developing effective therapies.
Attend InnoSer Poster Presentations
At InnoSer, we are committed to advancing neurodegenerative disease research by providing a broad range of preclinical research services using cellular and animal neurodegenerative disease models. Following our recent acquisition of a preclinical neurodegenerative disease CRO, Remynd, we are delighted to be able to share the latest developments from both companies with other experts in the neurodegenerative disease field at the prestigious ADPD 2025 Conference. Our study directors, Sofie Carmans (previously at remynd), PhD, Jolien Beeken, Phd and Thomas Vogels, PhD, will present new innovative research.
ADPD 2025 InnoSer’s Poster Presentations Details:
Poster #834: Proven Compound susceptible Tau[P301S] mouse model for preclinical proof of concept
Presentation time: April 2 from 8.00 to April 3rd until 18.30, poster board #584 (shift 1)
Tauopathies, including Alzheimer’s disease (AD) and frontotemporal dementia (FTD), are driven by the accumulation of hyperphosphorylated tau, which leads to neurodegeneration. Here we aimed to comprehensively characterize the Tau[P301S] mouse model. The objective was to evaluate the model’s potential in reflecting tau-driven pathology and its suitability for preclinical therapeutic testing.
Poster #814: Combination model for preclinical proof of concept studies targeting human alpha-synuclein pathology
Presentation time: April 2 from 8.00 to April 3rd until 18.30, poster board #584 (shift 1)
Parkinson’s disease (PD) is characterized by the pathological accumulation of α-synuclein (αSyn), positioning this protein as a critical biomarker and therapeutic target. Existing αSyn rodent models have provided valuable insights into PD pathogenesis, but many fail to fully capture the complexity and robustness of the disease’s pathology and behavior. Thus, a more comprehensive model that reflects a broader spectrum of PD pathology is needed to improve preclinical research.
Poster #1702: Characterization of in vitro neuronal and microglial disease models to support drug discovery eforts for neurodegenerative diseases
Presentation time: April 2 from 8.00 to April 3rd until 18.30, poster board #584 (shift 1)
The aim of the present study was to validate in vitro neuronal and microglial neurodegenerative disease models to enable screening of disease-modifying compounds.
Poster #1674: Phenotypic characterization of the transgenic human TDP-43(Q331K) mouse model of amyothrophic lateral sclerosis (ALS)
Presentation time: April 2 from 8.00 to April 3rd until 18.30, poster board #584 (shift 1)
TAR DNA binding protein 43 (TDP-43) encoded by the TARDBP gene, is a major pathological protein involved in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia. Although multiple preclinical research models of ALS exist, to date, mouse models with TDP-43 pathology have not been characterised in detail. Therefore, we performed an extensive phenotypic characterisation of the transgenic human TDP-43Q331K (Jackson Laboratories #017933) model to assess its suitability for preclinical efficacy studies.
Meet The InnoSer Team at Booth #43
ADPD 2025 represents a unique opportunity to interact with our team, therefore, in addition to our poster presentations, we invite you to stop by our booth to learn more about our comprehensive preclinical services. Our team will be available to discuss how our advanced models and expertise can support your neurodegenerative disease research and drug development efforts. You can meet the InnoSer study directors Sofie Carmans, PhD, Jolien Beeken, PhD, and Thomas Vogels, PhD, together with our business development manager Charlotte Wuyts, MSc, at booth #43.